Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

Bhatti, Maria; Ippolito, Thomas; Mavis, Cory; Gu, Juan; Cairo, Mitchell S; Lim, Megan S; Hernandez-Ilizaliturri, Francisco; Barth, Matthew J

Bhatti, Maria; Ippolito, Thomas; Mavis, Cory; Gu, Juan; Cairo, Mitchell S; Lim, Megan S; Hernandez-Ilizaliturri, Francisco; Barth, Matthew J.

Afiliação

Bhatti M; Department of Pediatric Hematology/Oncology, University at Buffalo, Buffalo, NY, USA.
Ippolito T; Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Mavis C; Department of Pediatric Hematology/Oncology, University at Buffalo, Buffalo, NY, USA.
Gu J; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Cairo MS; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Lim MS; Department of Pediatrics, Medicine, Pathology, Microbiology and Immunology, Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA.
Hernandez-Ilizaliturri F; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Barth MJ; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.

Oncotarget ; 9(31): 21820-21830, 2018 Apr 24.

Article em En | MEDLINE | ID: mdl-29774105

Palavras-chave

AKT; Burkitt; PI3K; idelalisib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google